Mirum Pharmaceuticals Inc (MIRM)
26.40
+0.56
(+2.17%)
USD |
NASDAQ |
May 06, 16:00
26.40
0.00 (0.00%)
After-Hours: 20:00
Mirum Pharmaceuticals Cash from Financing (Quarterly): 1.777M for Dec. 31, 2023
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 1.777M |
| September 30, 2023 | 207.13M |
| June 30, 2023 | 114.71M |
| March 31, 2023 | 12.99M |
| December 31, 2022 | -0.329M |
| September 30, 2022 | 86.07M |
| June 30, 2022 | 5.246M |
| March 31, 2022 | 18.10M |
| December 31, 2021 | 0.615M |
| September 30, 2021 | 0.345M |
| Date | Value |
|---|---|
| June 30, 2021 | 65.91M |
| March 31, 2021 | 6.594M |
| December 31, 2020 | 134.51M |
| September 30, 2020 | 2.096M |
| June 30, 2020 | 0.025M |
| March 31, 2020 | 44.66M |
| December 31, 2019 | 0.00 |
| September 30, 2019 | 68.42M |
| June 30, 2019 | 58.76M |
| March 31, 2019 | 0.00 |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-0.329M
Minimum
Dec 2022
207.13M
Maximum
Sep 2023
43.56M
Average
12.99M
Median
Mar 2023
Cash from Financing (Quarterly) Benchmarks
| Vanda Pharmaceuticals Inc | 0.00 |
| Sarepta Therapeutics Inc | 22.14M |
| Puma Biotechnology Inc | 0.00 |
| Reneo Pharmaceuticals Inc | -4.128M |
| Tharimmune Inc | 9.662M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -16.62M |
| Cash from Investing (Quarterly) | -2.00M |
| Free Cash Flow | -91.05M |
| Free Cash Flow Per Share (Quarterly) | -0.4637 |
| Free Cash Flow to Equity (Quarterly) | -22.02M |
| Free Cash Flow to Firm (Quarterly) | -21.62M |
| Free Cash Flow Yield | -8.44% |